Arrhythmias & electrophysiology
Single beta-blocker or combined amiodarone therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy—defibrillator patients: Insights from the German DEVICE registry
Main finding · 1-year overall mortalityResult — go to the resultAdjusted hazard ratio 2.09Authors' conclusion
Although amiodarone has no adverse effect on the success of defibrillation testing, our data suggest an increased all-cause mortality under amiodarone therapy, especially in the subgroups of patients with sinus rhythm or severely reduced left ventricular function. In surviving patients, rates of arrhythmic events were comparable.
Study context
- Population
- Patients undergoing implantable cardioverter-defibrillator (ICD) or CRT-D implantation, revision or upgrade, German DEVICE registry, March 2007–February 2014
- Participants
- 4,499 patients
- Exposure
- Beta-blocker plus amiodarone vs beta-blocker alone
- Outcome
- 1-year overall mortality
- Follow-up
- 1 year
Methodological detailsmulticentre, 49 centres
- Multicentre
- 49 centres
Main finding
As reported in the abstract
Adjusted hazard ratio
2.09
P < 0.001
Observational data: associations, not effects.
Further findings
Success of defibrillation testing
- No significant effect of amiodarone
ICD discharges or syncopal events (survivors)
- Amiodarone not associated with a significantly reduced risk
Ventricular tachycardia (VT) storm or incessant VTs; patients scheduled for intracardiac ablation
- Did not differ between groups
Rehospitalization
- Lower with beta-blocker alone
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →